Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Subjects with persi...
Saved in:
| Published in | Ophthalmology (Rochester, Minn.) Vol. 119; no. 10; pp. 2125 - 2132 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Elsevier Inc
01.10.2012
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME).
Two randomized, sham injection-controlled, double-masked, multicenter clinical trials.
Subjects with persistent DME despite ≥1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393).
Subjects received study drug or sham injection and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year.
Percentage of patients with improvement of ≥15 letters from baseline. Secondary outcomes included other parameters of visual function and foveal thickness.
At month 36, the percentage of patients who gained ≥15 in letter score using the last observation carried forward method was 28.7% (low dose) and 27.8% (high dose) in the FAc insert groups compared with 18.9% (P = 0.018) in the sham group, and considering only those patients still in the trial at month 36, it was 33.0% (low dose) and 31.9% (high dose) compared with 21.4% in the sham group (P = 0.030). Preplanned subgroup analysis demonstrated a doubling of benefit compared with sham injections in patients who reported duration of DME ≥3 years at baseline; the percentage who gained ≥15 in letter score at month 36 was 34.0% (low dose; P<0.001) or 28.8% (high dose; P = 0.002) compared with 13.4% (sham). An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13.7% (low dose) and 10.1% (high dose) compared with 8.9% in the sham group. Almost all phakic patients in the FAc insert groups developed cataract, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group.
In patients with DME FAc inserts provide substantial visual benefit for up to 3 years and would provide a valuable addition to the options available for patients with DME.
Proprietary or commercial disclosure may be found after the references. |
|---|---|
| AbstractList | Objective To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Design Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Participants Subjects with persistent DME despite ≥1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Methods Subjects received study drug or sham injection and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Main Outcome Measures Percentage of patients with improvement of ≥15 letters from baseline. Secondary outcomes included other parameters of visual function and foveal thickness. Results At month 36, the percentage of patients who gained ≥15 in letter score using the last observation carried forward method was 28.7% (low dose) and 27.8% (high dose) in the FAc insert groups compared with 18.9% ( P = 0.018) in the sham group, and considering only those patients still in the trial at month 36, it was 33.0% (low dose) and 31.9% (high dose) compared with 21.4% in the sham group ( P = 0.030). Preplanned subgroup analysis demonstrated a doubling of benefit compared with sham injections in patients who reported duration of DME ≥3 years at baseline; the percentage who gained ≥15 in letter score at month 36 was 34.0% (low dose; P <0.001) or 28.8% (high dose; P = 0.002) compared with 13.4% (sham). An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13.7% (low dose) and 10.1% (high dose) compared with 8.9% in the sham group. Almost all phakic patients in the FAc insert groups developed cataract, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group. Conclusions In patients with DME FAc inserts provide substantial visual benefit for up to 3 years and would provide a valuable addition to the options available for patients with DME. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME).OBJECTIVETo assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME).Two randomized, sham injection-controlled, double-masked, multicenter clinical trials.DESIGNTwo randomized, sham injection-controlled, double-masked, multicenter clinical trials.Subjects with persistent DME despite ≥1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393).PARTICIPANTSSubjects with persistent DME despite ≥1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393).Subjects received study drug or sham injection and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year.METHODSSubjects received study drug or sham injection and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year.Percentage of patients with improvement of ≥15 letters from baseline. Secondary outcomes included other parameters of visual function and foveal thickness.MAIN OUTCOME MEASURESPercentage of patients with improvement of ≥15 letters from baseline. Secondary outcomes included other parameters of visual function and foveal thickness.At month 36, the percentage of patients who gained ≥15 in letter score using the last observation carried forward method was 28.7% (low dose) and 27.8% (high dose) in the FAc insert groups compared with 18.9% (P = 0.018) in the sham group, and considering only those patients still in the trial at month 36, it was 33.0% (low dose) and 31.9% (high dose) compared with 21.4% in the sham group (P = 0.030). Preplanned subgroup analysis demonstrated a doubling of benefit compared with sham injections in patients who reported duration of DME ≥3 years at baseline; the percentage who gained ≥15 in letter score at month 36 was 34.0% (low dose; P<0.001) or 28.8% (high dose; P = 0.002) compared with 13.4% (sham). An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13.7% (low dose) and 10.1% (high dose) compared with 8.9% in the sham group. Almost all phakic patients in the FAc insert groups developed cataract, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group.RESULTSAt month 36, the percentage of patients who gained ≥15 in letter score using the last observation carried forward method was 28.7% (low dose) and 27.8% (high dose) in the FAc insert groups compared with 18.9% (P = 0.018) in the sham group, and considering only those patients still in the trial at month 36, it was 33.0% (low dose) and 31.9% (high dose) compared with 21.4% in the sham group (P = 0.030). Preplanned subgroup analysis demonstrated a doubling of benefit compared with sham injections in patients who reported duration of DME ≥3 years at baseline; the percentage who gained ≥15 in letter score at month 36 was 34.0% (low dose; P<0.001) or 28.8% (high dose; P = 0.002) compared with 13.4% (sham). An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13.7% (low dose) and 10.1% (high dose) compared with 8.9% in the sham group. Almost all phakic patients in the FAc insert groups developed cataract, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group.In patients with DME FAc inserts provide substantial visual benefit for up to 3 years and would provide a valuable addition to the options available for patients with DME.CONCLUSIONSIn patients with DME FAc inserts provide substantial visual benefit for up to 3 years and would provide a valuable addition to the options available for patients with DME. To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Subjects with persistent DME despite ≥1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Subjects received study drug or sham injection and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Percentage of patients with improvement of ≥15 letters from baseline. Secondary outcomes included other parameters of visual function and foveal thickness. At month 36, the percentage of patients who gained ≥15 in letter score using the last observation carried forward method was 28.7% (low dose) and 27.8% (high dose) in the FAc insert groups compared with 18.9% (P = 0.018) in the sham group, and considering only those patients still in the trial at month 36, it was 33.0% (low dose) and 31.9% (high dose) compared with 21.4% in the sham group (P = 0.030). Preplanned subgroup analysis demonstrated a doubling of benefit compared with sham injections in patients who reported duration of DME ≥3 years at baseline; the percentage who gained ≥15 in letter score at month 36 was 34.0% (low dose; P<0.001) or 28.8% (high dose; P = 0.002) compared with 13.4% (sham). An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13.7% (low dose) and 10.1% (high dose) compared with 8.9% in the sham group. Almost all phakic patients in the FAc insert groups developed cataract, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group. In patients with DME FAc inserts provide substantial visual benefit for up to 3 years and would provide a valuable addition to the options available for patients with DME. Proprietary or commercial disclosure may be found after the references. To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Subjects with persistent DME despite ≥1 macular laser treatment were randomized 1:2:2 to sham injection (n = 185), low-dose insert (n = 375), or high-dose insert (n = 393). Subjects received study drug or sham injection and after 6 weeks were eligible for rescue laser. Based on retreatment criteria, additional study drug or sham injections could be given after 1 year. Percentage of patients with improvement of ≥15 letters from baseline. Secondary outcomes included other parameters of visual function and foveal thickness. At month 36, the percentage of patients who gained ≥15 in letter score using the last observation carried forward method was 28.7% (low dose) and 27.8% (high dose) in the FAc insert groups compared with 18.9% (P = 0.018) in the sham group, and considering only those patients still in the trial at month 36, it was 33.0% (low dose) and 31.9% (high dose) compared with 21.4% in the sham group (P = 0.030). Preplanned subgroup analysis demonstrated a doubling of benefit compared with sham injections in patients who reported duration of DME ≥3 years at baseline; the percentage who gained ≥15 in letter score at month 36 was 34.0% (low dose; P<0.001) or 28.8% (high dose; P = 0.002) compared with 13.4% (sham). An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13.7% (low dose) and 10.1% (high dose) compared with 8.9% in the sham group. Almost all phakic patients in the FAc insert groups developed cataract, but their visual benefit after cataract surgery was similar to that in pseudophakic patients. The incidence of incisional glaucoma surgery at month 36 was 4.8% in the low-dose group and 8.1% in the high-dose insert group. In patients with DME FAc inserts provide substantial visual benefit for up to 3 years and would provide a valuable addition to the options available for patients with DME. |
| Author | Chen, Sanford Hariprasad, Seenu M. Kapik, Barry Boyer, David Billman, Kathleen Gupta, Amod Kane, Frances E. Garretson, Bruce Ruiz-Moreno, Jose Reichel, Elias Soubrane, Gisele Campochiaro, Peter A. Green, Kenneth Brown, David M. Pearson, Andrew Bailey, Clare |
| Author_xml | – sequence: 1 givenname: Peter A. surname: Campochiaro fullname: Campochiaro, Peter A. email: pcampo@jhmi.edu organization: Wilmer Eye Institute, Baltimore, Maryland – sequence: 2 givenname: David M. surname: Brown fullname: Brown, David M. organization: Vitreoretinal Consultants, Houston, Texas – sequence: 3 givenname: Andrew surname: Pearson fullname: Pearson, Andrew organization: Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky – sequence: 4 givenname: Sanford surname: Chen fullname: Chen, Sanford organization: Orange County Retina Medical Group, Santa Ana, California – sequence: 5 givenname: David surname: Boyer fullname: Boyer, David organization: Retina Vitreous Associates Medical Group, Beverly Hills, California – sequence: 6 givenname: Jose surname: Ruiz-Moreno fullname: Ruiz-Moreno, Jose organization: Institut Oflalmologico Alicante, Spain – sequence: 7 givenname: Bruce surname: Garretson fullname: Garretson, Bruce organization: Royal Oak Associates, Royal Oak, Michigan – sequence: 8 givenname: Amod surname: Gupta fullname: Gupta, Amod organization: Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India – sequence: 9 givenname: Seenu M. surname: Hariprasad fullname: Hariprasad, Seenu M. organization: Department of Ophthalmlogy, University of Chicago, Chicago, Illinois – sequence: 10 givenname: Clare surname: Bailey fullname: Bailey, Clare organization: Bristol Eye Hospital, Bristol, UK – sequence: 11 givenname: Elias surname: Reichel fullname: Reichel, Elias organization: Tufts Medical Center Hospital, Boston, Massachusetts – sequence: 12 givenname: Gisele surname: Soubrane fullname: Soubrane, Gisele organization: Intercommunal Hospital of Creteil, Creteil, France – sequence: 13 givenname: Barry surname: Kapik fullname: Kapik, Barry organization: Alimera Sciences, Atlanta, Georgia – sequence: 14 givenname: Kathleen surname: Billman fullname: Billman, Kathleen organization: Alimera Sciences, Atlanta, Georgia – sequence: 15 givenname: Frances E. surname: Kane fullname: Kane, Frances E. organization: Alimera Sciences, Atlanta, Georgia – sequence: 16 givenname: Kenneth surname: Green fullname: Green, Kenneth organization: Alimera Sciences, Atlanta, Georgia |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26818699$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22727177$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVks2KFDEUhYOMOD2jbyCSjeCm2vxVpUpkYJwfHWhxYFRwFVKpW3Ta6qRNUi39BL62KbpVEGRwlUW-cy73nHuCjpx3gNBTSuaU0Orlau43y7TUc0YomxMxJ5w8QDNaiqYQkvIjNMsYLSrByDE6iXFFCKkqLh6hY8Ykk1TKGfpxN8akrYMOX8JgtxB2-HoYvbHOD3kgPjeQvLMd4M82BfBjxDcuQkgR3wa_nT7egIPeJtz7gHXCC9AxYY6_gA4RW4dvdbLgsuC7TUt8aXULyRr8Xptx0AFfdbDWj9HDXg8RnhzeU_Tp-urjxbti8eHtzcX5ojAlIalo-kbXTS2E4QJk31dMlF0Fte6AlbJlQnADuqFNzXhHWi40lbyHVnLOZdkyfope7H03wX8bISa1ttHAMGg37aYoabioSV2WGX12QMd2DZ3aBLvWYad-hZeB5wdAR6OHPmhnbPzDVTWtq6bJnNhzJvgYA_S_EUrU1KVaqX2XaupSEaFyl1n26i-ZsSlH6V0K2g73ic_2Yshhbi0EFU0uwUBnA5ikOm__18AM1tm851fYQVz5MbhclKIqZo26m25tOjXKCBGETUm__rfB_fN_Amdc5ac |
| CODEN | OPHTDG |
| CitedBy_id | crossref_primary_10_1111_dme_12089 crossref_primary_10_1055_a_1024_4089 crossref_primary_10_1007_s40135_020_00225_1 crossref_primary_10_1016_j_ajo_2020_03_016 crossref_primary_10_1177_1120672120930603 crossref_primary_10_3390_pharmaceutics13101548 crossref_primary_10_3928_23258160_20200501_09 crossref_primary_10_1016_j_addr_2021_04_007 crossref_primary_10_31348_2023_27 crossref_primary_10_1038_s41598_018_24197_2 crossref_primary_10_1016_j_xops_2022_100192 crossref_primary_10_1097_IAE_0000000000001038 crossref_primary_10_1177_2042018813512360 crossref_primary_10_4155_tde_2018_0006 crossref_primary_10_1136_bjophthalmol_2017_310737 crossref_primary_10_12968_hmed_2015_76_1_35 crossref_primary_10_1007_s40265_015_0447_1 crossref_primary_10_1007_s11892_013_0410_z crossref_primary_10_1016_j_diabres_2017_01_013 crossref_primary_10_3390_pharmaceutics14040723 crossref_primary_10_1016_j_jfo_2025_104487 crossref_primary_10_1016_j_jfo_2015_08_002 crossref_primary_10_1177_1120672119834474 crossref_primary_10_2147_OPTH_S289800 crossref_primary_10_1136_bmjophth_2020_000484 crossref_primary_10_1056_NEJMra1909637 crossref_primary_10_1111_dom_12384 crossref_primary_10_12688_f1000research_12662_1 crossref_primary_10_1007_s00592_019_01439_x crossref_primary_10_1016_j_preteyeres_2016_09_003 crossref_primary_10_1172_jci_insight_93751 crossref_primary_10_4103_tjo_tjo_68_19 crossref_primary_10_1016_j_jcjo_2012_11_012 crossref_primary_10_1097_IAE_0000000000000876 crossref_primary_10_1177_11206721211020203 crossref_primary_10_1016_j_diabet_2019_04_002 crossref_primary_10_3390_ijms22084020 crossref_primary_10_1177_11206721221097587 crossref_primary_10_1097_ICB_0000000000000779 crossref_primary_10_1016_j_ajo_2013_11_012 crossref_primary_10_1007_s40123_015_0028_0 crossref_primary_10_1007_s00125_016_3974_8 crossref_primary_10_1055_a_1271_2043 crossref_primary_10_1097_IIO_0000000000000191 crossref_primary_10_1177_11206721241237069 crossref_primary_10_1186_s12886_018_0726_1 crossref_primary_10_3389_fphar_2022_824790 crossref_primary_10_3390_jcm9092848 crossref_primary_10_1016_j_phrs_2019_104299 crossref_primary_10_1111_aos_12803 crossref_primary_10_4155_tde_2019_0081 crossref_primary_10_1097_IIO_0000000000000198 crossref_primary_10_2174_1574886315666200902154322 crossref_primary_10_3390_cells11213362 crossref_primary_10_1097_IIO_0000000000000075 crossref_primary_10_1007_s40123_017_0114_6 crossref_primary_10_1186_s12886_015_0148_2 crossref_primary_10_5662_wjm_v14_i4_95881 crossref_primary_10_1016_j_oret_2017_05_003 crossref_primary_10_1080_03007995_2017_1366663 crossref_primary_10_1517_14656566_2015_1100172 crossref_primary_10_1080_03007995_2017_1366662 crossref_primary_10_1007_s11892_015_0669_3 crossref_primary_10_1080_14728222_2021_2005026 crossref_primary_10_1177_24741264231201314 crossref_primary_10_1080_03007995_2020_1754183 crossref_primary_10_1016_j_jfo_2017_01_003 crossref_primary_10_1007_s13346_020_00843_z crossref_primary_10_12688_f1000research_8265_1 crossref_primary_10_1016_j_jfo_2014_09_007 crossref_primary_10_1080_08820538_2016_1228388 crossref_primary_10_17352_2455_1414_000011 crossref_primary_10_2217_imt_16_5 crossref_primary_10_1007_s00417_018_3952_6 crossref_primary_10_1155_2014_164692 crossref_primary_10_1111_bcp_12371 crossref_primary_10_1007_s40135_016_0093_0 crossref_primary_10_1136_bmjophth_2019_000271 crossref_primary_10_1007_s00592_012_0449_3 crossref_primary_10_1080_00325481_2015_1052523 crossref_primary_10_1586_17469899_2014_956725 crossref_primary_10_1097_ICU_0000000000000143 crossref_primary_10_1038_s41598_022_17555_8 crossref_primary_10_1055_a_2419_1794 crossref_primary_10_1097_IIO_0000000000000518 crossref_primary_10_1038_eye_2016_301 crossref_primary_10_33590_emjdiabet_10310409 crossref_primary_10_3928_23258160_20201104_10 crossref_primary_10_1186_s40942_021_00288_7 crossref_primary_10_1007_s00592_019_01453_z crossref_primary_10_1097_APO_0000000000000121 crossref_primary_10_1097_IAE_0b013e318296b271 crossref_primary_10_1177_11206721211046718 crossref_primary_10_1038_s41433_023_02667_w crossref_primary_10_1080_14656566_2017_1363182 crossref_primary_10_1016_j_survophthal_2020_01_002 crossref_primary_10_3390_jcm10173966 crossref_primary_10_1016_j_visres_2017_03_006 crossref_primary_10_1080_17469899_2018_1523720 crossref_primary_10_1089_jop_2014_0100 crossref_primary_10_1136_bmjophth_2020_000696 crossref_primary_10_1517_14656566_2014_896899 crossref_primary_10_1038_eye_2017_125 crossref_primary_10_1097_ICU_0000000000000031 crossref_primary_10_1080_14740338_2022_2160442 crossref_primary_10_1111_ceo_13702 crossref_primary_10_1097_ICU_0b013e32835fab27 crossref_primary_10_1097_IIO_0000000000000132 crossref_primary_10_1097_IIO_0000000000000253 crossref_primary_10_1016_j_jcjd_2017_10_027 crossref_primary_10_1007_s40123_023_00749_2 crossref_primary_10_1016_j_ophtha_2014_04_019 crossref_primary_10_1080_03007995_2017_1366645 crossref_primary_10_1097_ICU_0000000000000953 crossref_primary_10_1080_14656566_2020_1713093 crossref_primary_10_1177_2515841420917768 crossref_primary_10_17925_EOR_2019_13_1_44 crossref_primary_10_1007_s11428_016_0140_3 crossref_primary_10_1016_j_survophthal_2024_07_002 crossref_primary_10_1016_j_ecl_2022_06_004 crossref_primary_10_1016_j_ophtha_2014_04_024 crossref_primary_10_3390_jcm13051327 crossref_primary_10_1016_j_ophtha_2013_02_018 crossref_primary_10_1136_bjophthalmol_2018_312284 crossref_primary_10_1016_j_biomaterials_2017_02_006 crossref_primary_10_1016_j_preteyeres_2015_06_002 crossref_primary_10_1155_2014_989501 crossref_primary_10_1155_2018_3420187 crossref_primary_10_1177_24741264231218044 crossref_primary_10_17925_EOR_2018_12_2_88 crossref_primary_10_3390_pharmaceutics15071862 crossref_primary_10_1097_IAE_0000000000001369 crossref_primary_10_22608_APO_2017529 crossref_primary_10_1097_IAE_0000000000001004 crossref_primary_10_1177_11206721221124688 crossref_primary_10_1016_j_yaoo_2019_04_016 crossref_primary_10_1155_2017_8234186 crossref_primary_10_1177_1120672119898414 crossref_primary_10_1007_s00417_022_05564_2 crossref_primary_10_5318_wjo_v5_i2_55 crossref_primary_10_1080_03007995_2017_1366659 crossref_primary_10_1016_j_gene_2023_147212 crossref_primary_10_1080_01478885_2022_2137665 crossref_primary_10_3928_23258160_20170329_03 crossref_primary_10_1007_s40265_013_0010_x crossref_primary_10_1111_ceo_12999 crossref_primary_10_1155_2013_689276 crossref_primary_10_1124_jpet_119_256933 crossref_primary_10_1177_2040622315590319 crossref_primary_10_4155_cli_15_1 crossref_primary_10_1007_s40265_017_0704_6 crossref_primary_10_1016_j_visres_2017_07_006 crossref_primary_10_1097_IAE_0000000000000726 crossref_primary_10_2147_OPTH_S252359 crossref_primary_10_3390_ijms22179441 crossref_primary_10_3928_23258160_20160419_04 crossref_primary_10_3928_23258160_20160419_05 crossref_primary_10_1007_s40123_022_00613_9 crossref_primary_10_1016_j_preteyeres_2023_101187 crossref_primary_10_3390_pharmaceutics13010072 crossref_primary_10_1177_11206721231183471 crossref_primary_10_1136_bjophthalmol_2015_307136 crossref_primary_10_1007_s10354_024_01070_8 crossref_primary_10_1016_j_jfo_2015_03_002 crossref_primary_10_1080_17425247_2016_1198771 crossref_primary_10_3109_10837450_2014_920358 crossref_primary_10_1080_14728214_2020_1810664 crossref_primary_10_1159_000540459 crossref_primary_10_1186_s12886_022_02357_3 crossref_primary_10_1080_17469899_2017_1351296 crossref_primary_10_1055_a_2074_9102 crossref_primary_10_3928_23258160_20200401_03 crossref_primary_10_1080_03007995_2018_1560779 crossref_primary_10_1007_s40123_022_00504_z crossref_primary_10_1159_000354548 crossref_primary_10_1177_11206721231217525 crossref_primary_10_1155_2021_6678364 crossref_primary_10_3390_pharmaceutics13091491 crossref_primary_10_3928_23258160_20230615_02 crossref_primary_10_7759_cureus_52676 crossref_primary_10_1038_eye_2015_98 crossref_primary_10_1038_s41433_021_01921_3 crossref_primary_10_1097_IAE_0000000000001826 crossref_primary_10_1167_tvst_9_11_27 crossref_primary_10_1016_j_oret_2017_10_016 crossref_primary_10_1586_17469899_2014_902310 crossref_primary_10_1007_s40123_016_0045_7 crossref_primary_10_1177_1759720X20951733 crossref_primary_10_1159_000515306 crossref_primary_10_1159_000480119 crossref_primary_10_1177_11206721241235266 crossref_primary_10_3389_fendo_2023_1106706 crossref_primary_10_1007_s40265_017_0722_4 crossref_primary_10_1097_IAE_0000000000001555 crossref_primary_10_1002_14651858_CD011599_pub2 crossref_primary_10_1159_000362764 crossref_primary_10_1177_11206721221128671 crossref_primary_10_1177_1120672118781236 crossref_primary_10_1186_s40662_021_00261_3 crossref_primary_10_2147_OPTH_S238740 crossref_primary_10_1136_bjophthalmol_2015_307950 crossref_primary_10_2147_DDDT_S383101 crossref_primary_10_1007_s15034_018_1236_1 crossref_primary_10_5005_hov_10102_08303 crossref_primary_10_1002_14651858_CD011599 crossref_primary_10_1177_0300060518816884 crossref_primary_10_3928_23258160_20230215_01 crossref_primary_10_1080_1061186X_2017_1280809 crossref_primary_10_1016_j_ophtha_2020_04_001 crossref_primary_10_1177_11206721221080288 crossref_primary_10_5301_ejo_5000581 crossref_primary_10_1017_S0952523820000048 crossref_primary_10_1136_bmjophth_2019_000405 crossref_primary_10_1016_j_ophtha_2022_01_015 crossref_primary_10_1080_17469899_2018_1520634 crossref_primary_10_1517_14740338_2015_1041916 crossref_primary_10_1089_jop_2015_0133 crossref_primary_10_1586_17512433_2016_1133287 crossref_primary_10_1097_IAE_0000000000003080 crossref_primary_10_1152_ajpheart_00001_2022 crossref_primary_10_1080_17469899_2020_1729743 crossref_primary_10_1097_IAE_0000000000003081 crossref_primary_10_1177_2474126419834711 crossref_primary_10_1038_s41433_021_01542_w crossref_primary_10_1007_s10571_021_01077_4 crossref_primary_10_1080_14656566_2023_2230139 crossref_primary_10_1159_000368840 crossref_primary_10_1097_IAE_0000000000000490 crossref_primary_10_1136_bmjopen_2018_022031 crossref_primary_10_1016_j_ophtha_2015_09_051 crossref_primary_10_2147_OPTH_S267521 crossref_primary_10_1155_2013_780634 crossref_primary_10_1002_pdi_1884 crossref_primary_10_1136_bmjophth_2019_000416 crossref_primary_10_3390_pharmaceutics14112391 crossref_primary_10_1007_s40123_020_00297_z crossref_primary_10_4103_ijo_IJO_1028_20 crossref_primary_10_12688_f1000research_19198_1 crossref_primary_10_2147_DDDT_S403259 crossref_primary_10_1007_s00347_016_0223_y crossref_primary_10_1080_14712598_2023_2247987 crossref_primary_10_1080_17469899_2024_2362162 crossref_primary_10_3390_diagnostics12102415 crossref_primary_10_3928_23258160_20231109_02 crossref_primary_10_1111_ceo_13894 crossref_primary_10_3389_fmed_2021_725349 crossref_primary_10_1007_s40123_019_00209_w crossref_primary_10_1136_bjo_2022_321415 crossref_primary_10_2147_OPTH_S253370 crossref_primary_10_1007_s12325_021_01751_5 crossref_primary_10_1136_bmjophth_2020_000620 crossref_primary_10_1159_000499540 crossref_primary_10_1007_s00347_019_01015_2 crossref_primary_10_1016_j_xops_2023_100403 crossref_primary_10_4103_1673_5374_355743 crossref_primary_10_1016_j_oret_2024_07_004 crossref_primary_10_4103_pajo_pajo_3_23 crossref_primary_10_3390_ijms24119591 crossref_primary_10_2147_OPTH_S283561 crossref_primary_10_1007_s10792_023_02864_2 crossref_primary_10_1016_j_ajo_2022_09_017 crossref_primary_10_1097_IAE_0000000000001234 crossref_primary_10_1177_2515841418820755 crossref_primary_10_1038_s41433_025_03692_7 crossref_primary_10_1080_14728214_2020_1801631 crossref_primary_10_1155_2013_213130 crossref_primary_10_2147_OPTH_S262085 crossref_primary_10_3928_23258160_20170829_06 crossref_primary_10_3390_pharmaceutics15071959 crossref_primary_10_2147_IMCRJ_S295045 crossref_primary_10_1016_j_cyto_2017_02_013 crossref_primary_10_25259_AJOCT_7_2018 crossref_primary_10_1186_s12886_015_0178_9 crossref_primary_10_1038_s41598_021_84362_y crossref_primary_10_18229_kocatepetip_346227 crossref_primary_10_1007_s40123_019_0197_3 crossref_primary_10_1016_j_ophtha_2021_07_009 crossref_primary_10_2147_OPTH_S318026 crossref_primary_10_14341_DM8328 crossref_primary_10_3928_23258160_20150304_01 crossref_primary_10_4103_0301_4738_178142 crossref_primary_10_3390_genes14112012 crossref_primary_10_1016_j_oret_2022_04_009 crossref_primary_10_1080_14728214_2019_1663823 crossref_primary_10_1007_s40123_018_0155_5 crossref_primary_10_1517_14712598_2016_1131265 crossref_primary_10_3928_23258160_20160224_01 crossref_primary_10_1007_s40135_017_0134_3 crossref_primary_10_1517_17425247_2014_927864 crossref_primary_10_1007_s00210_022_02287_3 crossref_primary_10_1007_s40123_022_00460_8 crossref_primary_10_3928_23258160_20160324_01 crossref_primary_10_1038_s41433_021_01722_8 crossref_primary_10_1007_s10787_023_01143_x crossref_primary_10_1007_s11892_019_1276_5 crossref_primary_10_1038_s41433_020_01373_1 crossref_primary_10_1159_000489535 crossref_primary_10_1080_17425247_2016_1188800 crossref_primary_10_15275_rusomj_2022_0213 crossref_primary_10_1097_IAE_0000000000003827 crossref_primary_10_1186_s12348_019_0168_9 crossref_primary_10_3390_biomedicines13020248 crossref_primary_10_1016_j_oret_2017_06_010 crossref_primary_10_3928_23258160_20200228_01 crossref_primary_10_3389_fbioe_2020_549089 crossref_primary_10_1016_j_preteyeres_2023_101219 crossref_primary_10_1177_1120672120982948 crossref_primary_10_1007_s40123_020_00324_z crossref_primary_10_1007_s40265_020_01314_y crossref_primary_10_1016_j_ophtha_2016_11_034 crossref_primary_10_3928_23258160_20180831_08 crossref_primary_10_1136_bjophthalmol_2016_308388 crossref_primary_10_1136_bjophthalmol_2020_315984 crossref_primary_10_3390_pharmaceutics13020288 crossref_primary_10_1016_j_semarthrit_2019_06_004 crossref_primary_10_1080_07853890_2022_2064541 crossref_primary_10_1517_17425255_2014_922543 crossref_primary_10_4093_dmj_2014_38_6_416 crossref_primary_10_1007_s40123_016_0052_8 crossref_primary_10_1016_j_jfo_2023_05_001 crossref_primary_10_1038_eye_2016_174 crossref_primary_10_1007_s11892_019_1188_4 crossref_primary_10_1007_s00347_020_01244_w crossref_primary_10_1016_j_jfo_2023_05_003 crossref_primary_10_1136_bmjopen_2012_002269 crossref_primary_10_1016_j_jfo_2014_08_003 crossref_primary_10_1038_s41433_022_02338_2 crossref_primary_10_1155_2015_352487 crossref_primary_10_1080_09273948_2024_2435472 crossref_primary_10_1177_1120672119857511 crossref_primary_10_3390_pharmaceutics16091183 crossref_primary_10_3928_23258160_20160901_01 crossref_primary_10_1007_s40123_018_0145_7 crossref_primary_10_1080_17469899_2017_1285698 crossref_primary_10_1007_s00347_015_0127_2 crossref_primary_10_1177_24741264241247624 crossref_primary_10_2147_OPTH_S382920 crossref_primary_10_1097_IAE_0000000000001547 crossref_primary_10_1097_IAE_0000000000001548 crossref_primary_10_1080_17425247_2016_1182488 crossref_primary_10_1177_1120672121992982 crossref_primary_10_1080_13543784_2020_1763953 crossref_primary_10_1007_s40135_014_0051_7 crossref_primary_10_1177_2474126420943417 |
| Cites_doi | 10.1016/j.ophtha.2011.12.039 10.1016/j.ophtha.2009.11.024 10.1001/archopht.1985.01050120030015 10.1016/j.ophtha.2010.12.028 |
| ContentType | Journal Article |
| Copyright | 2012 American Academy of Ophthalmology American Academy of Ophthalmology 2014 INIST-CNRS Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2012 American Academy of Ophthalmology – notice: American Academy of Ophthalmology – notice: 2014 INIST-CNRS – notice: Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| CorporateAuthor | FAME Study Group |
| CorporateAuthor_xml | – name: FAME Study Group |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ophtha.2012.04.030 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-4713 |
| EndPage | 2132 |
| ExternalDocumentID | 22727177 26818699 10_1016_j_ophtha_2012_04_030 S0161642012004022 1_s2_0_S0161642012004022 |
| Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Novartis |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1B1 1CY 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ACVFH ADCNI ADMUD ADNMO AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGQPQ AIGII AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NQ- O9- OF- OPF OQ~ P2P R2- ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP ADPAM RIG AAIAV AGZHU AHPSJ ALXNB ZA5 AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c500t-9f9a89844c34e7ff6245d6e8ade257b2443cea919823d0b34a173feb733375b23 |
| ISSN | 0161-6420 1549-4713 |
| IngestDate | Fri Jul 11 04:48:36 EDT 2025 Mon Jul 21 06:07:09 EDT 2025 Wed Apr 02 07:26:42 EDT 2025 Thu Apr 24 23:07:46 EDT 2025 Tue Jul 01 03:37:24 EDT 2025 Fri Feb 23 02:14:12 EST 2024 Sun Feb 23 10:19:55 EST 2025 Tue Aug 26 19:02:58 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Endocrinopathy Human Corticosteroid Retinopathy Steroid hormone Diabetes mellitus Vitreous body Retinal edema Eye disease Fluocinolone acetonide Adrenal hormone Delivery Ophthalmology |
| Language | English |
| License | CC BY 4.0 Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c500t-9f9a89844c34e7ff6245d6e8ade257b2443cea919823d0b34a173feb733375b23 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 22727177 |
| PQID | 1093480855 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1093480855 pubmed_primary_22727177 pascalfrancis_primary_26818699 crossref_primary_10_1016_j_ophtha_2012_04_030 crossref_citationtrail_10_1016_j_ophtha_2012_04_030 elsevier_sciencedirect_doi_10_1016_j_ophtha_2012_04_030 elsevier_clinicalkeyesjournals_1_s2_0_S0161642012004022 elsevier_clinicalkey_doi_10_1016_j_ophtha_2012_04_030 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-10-01 |
| PublicationDateYYYYMMDD | 2012-10-01 |
| PublicationDate_xml | – month: 10 year: 2012 text: 2012-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States |
| PublicationTitle | Ophthalmology (Rochester, Minn.) |
| PublicationTitleAlternate | Ophthalmology |
| PublicationYear | 2012 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Campochiaro, Brown, Pearson (bib2) 2011; 118 Campochiaro, Hafiz, Shah (bib1) 2010; 117 (bib3) 1985; 103 Nguyen, Brown, Marcus (bib4) 2012; 119 (10.1016/j.ophtha.2012.04.030_bib3) 1985; 103 Nguyen (10.1016/j.ophtha.2012.04.030_bib4) 2012; 119 Campochiaro (10.1016/j.ophtha.2012.04.030_bib1) 2010; 117 Campochiaro (10.1016/j.ophtha.2012.04.030_bib2) 2011; 118 |
| References_xml | – volume: 118 start-page: 626 year: 2011 end-page: 635 ident: bib2 article-title: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema publication-title: Ophthalmology – volume: 119 start-page: 789 year: 2012 end-page: 801 ident: bib4 article-title: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE publication-title: Ophthalmology – volume: 103 start-page: 1796 year: 1985 end-page: 1806 ident: bib3 article-title: Photocoagulation for diabetic macular edema publication-title: Arch Ophthalmol – volume: 117 start-page: 1393 year: 2010 end-page: 1399 ident: bib1 article-title: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert publication-title: Ophthalmology – volume: 119 start-page: 789 year: 2012 ident: 10.1016/j.ophtha.2012.04.030_bib4 article-title: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.12.039 – volume: 117 start-page: 1393 year: 2010 ident: 10.1016/j.ophtha.2012.04.030_bib1 article-title: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.11.024 – volume: 103 start-page: 1796 year: 1985 ident: 10.1016/j.ophtha.2012.04.030_bib3 article-title: Photocoagulation for diabetic macular edema publication-title: Arch Ophthalmol doi: 10.1001/archopht.1985.01050120030015 – volume: 118 start-page: 626 year: 2011 ident: 10.1016/j.ophtha.2012.04.030_bib2 article-title: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.12.028 |
| SSID | ssj0006634 |
| Score | 2.5618198 |
| Snippet | To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients... Objective To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2125 |
| SubjectTerms | Antihypertensive Agents - therapeutic use Biological and medical sciences Cataract - etiology Cataract - therapy Delivery. Postpartum. Lactation Diabetes. Impaired glucose tolerance Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Double-Blind Method Drug Implants Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fluocinolone Acetonide - administration & dosage Fluocinolone Acetonide - adverse effects Fluorescein Angiography Follow-Up Studies Glaucoma - etiology Glaucoma - surgery Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Gynecology. Andrology. Obstetrics Humans Macular Edema - diagnosis Macular Edema - drug therapy Medical sciences Miscellaneous Ophthalmology Phacoemulsification Retinopathies Tomography, Optical Coherence Trabeculectomy Treatment Outcome Visual Acuity - physiology Vitreous Body |
| Title | Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0161642012004022 https://www.clinicalkey.es/playcontent/1-s2.0-S0161642012004022 https://dx.doi.org/10.1016/j.ophtha.2012.04.030 https://www.ncbi.nlm.nih.gov/pubmed/22727177 https://www.proquest.com/docview/1093480855 |
| Volume | 119 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyEkhLhTLpOReKtSxXZufsyqjpbRdupWNp6iXBytUwnVkj7AH-CH8cc4jp00ZZs6eImiKE5kn8_nHB9_5xihDxHhCU9ZYqSJGxtWQpkRWrFppJEH9o2AzjRlovB44gzn1qdz-7zV-t1gLa2LqBf_vDGv5H-kCs9ArjJL9h8kW38UHsA9yBeuIGG43knGJyr7SUgy8VISLH50D5drGG4ZLAfv0Y8FuHaLRHS_LIorIdmuo0xuv-cyQUBm4HUPQNeli0KRKQtZbjUvuqz7FSZAyZQ9VnVXdRKc4s8sYnleUclfHSRCK3bt4E5XF8VFuPymSjuV8Ql9JJci6WdZrxF86Pvj42l_OPJn05os3IiuzqZnk5p4v4nbzgaj_nDwWbPSwnpVcDKdH8z8Scnv_FgeI9WMaRBas-N0oE17Bc24p0MMWCqZW4pbK1uNUHNLD6t0am3TKVFB1Gv2QoUuLnvfy8GRTD9aVr7Ve0Vb5bn_Mps1mZE6siog5_fQHoW1Cm2jPf9odnZUOwQAel1iXvWhyuAsaYbX_3ybh_RwFeYwb1N14MrtK6LSMzp9jB7pJQ32FT6foJbInqL7Y03aeIZ-1TDFFUxxE6a4himuYIo1TLGGKdYwxQBTHBa4hClmuIQpXmS4gimWMMUVTLGGKS5h-hzNDwen_aGhz_8wYts0C4OnPPS4Z1kxs4Sbpg617MQRXpgIMDQROKYsFiEn3KMsMSNmhcRlqYhcxphrR5S9QO0MuvEKYSfkwkliTqhM3mOmF7uceNyKOE3SxLI7iFVjHsS6OL48o2UZVCzIy0BJKpCSCkwrAEl1kFG3WqniMDvetytxBlXiM5jqANC4o517UzuRa12UByTI4WVJ1XSIhBiRahLc82ZL7VIrV_kO_9zfwlvdwQruHfS-AmAAJknuM4aZhIgktTDLkwTYDnqpkLlpTWHBRFz39a7Pv0EPNprhLWoXV2vxDvz_ItrX8-sPp8MFqA |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+Delivery+Fluocinolone+Acetonide+Vitreous+Inserts+Provide+Benefit+for+at+Least+3+Years+in+Patients+with+Diabetic+Macular+Edema&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=CAMPOCHIARO%2C+Peter+A&rft.au=BROWN%2C+David+M&rft.au=REICHEL%2C+Elias&rft.au=SOUBRANE%2C+Gisele&rft.date=2012-10-01&rft.pub=Elsevier&rft.issn=0161-6420&rft.volume=119&rft.issue=10&rft.spage=2125&rft.epage=2132&rft_id=info:doi/10.1016%2Fj.ophtha.2012.04.030&rft.externalDBID=n%2Fa&rft.externalDocID=26818699 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642011X00209%2Fcov150h.gif |